RxDoctor Payments Data

Sharon Barentine

Optometrist · Siler City, NCNPI 1467442194

Payments from drug & device makers

$1,908in general payments, 2019–2025

Across 82 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$313
  • Bausch & Lomb Americas Inc.$261
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$204
  • Aerie Pharmaceuticals, Inc.$202
  • Tarsus Pharmaceuticals, Inc.$189
  • Sun Pharmaceutical Industries Inc.$183
  • plus $557 from 8 others

What the payments were for

  • Food & beverage$1,908100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,908 in reported general payments places this provider in the 65th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$60,644
Medicare patients
311
Services billed
832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine84$124,803
LumiganBimatoprost30$13,660
Cyclosporine21$13,611
TyrvayaVarenicline Tartrate12$8,016
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol43$6,842
Alphagan PBrimonidine Tartrate11$5,924
CombiganBrimonidine Tartrate/Timolol12$2,296
Latanoprost255$2,170
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat96$1,946
Loteprednol Etabonate12$1,943
Fluorometholone23$1,483
Timolol Maleate94$945
Prednisolone Acetate32$794
Brimonidine Tartrate15$601
Dorzolamide Hcl23$432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$313$146,683137 claims
Oyster Point Pharma, Inc.Tyrvaya$96$8,01612 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$204$1,94312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Siler City

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →